Atreca Inc is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Atreca employs 134 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Atreca
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BCEL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Active traders

Atreca stock price (NASDAQ: BCEL)
Use our graph to track the performance of BCEL stocks over time.Atreca shares at a glance
Latest market close | $2.23 |
---|---|
52-week range | $1.51 - $9.77 |
50-day moving average | $1.87 |
200-day moving average | $3.26 |
Wall St. target price | $14.89 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.91 |
Buy Atreca shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Atreca stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Atreca price performance over time
Historical closes compared with the close of $2.23 from 2022-07-05
1 week (2022-06-29) | 21.86% |
---|---|
1 month (2022-06-02) | 42.95% |
3 months (2022-04-05) | -28.06% |
6 months (2022-01-02) | N/A |
1 year (2021-07-06) | -74.69% |
---|---|
2 years (2020-07-06) | -90.38% |
3 years (2019-07-05) | 16.22 |
5 years (2017-07-02) | N/A |
Atreca financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -28.86% |
Return on equity TTM | -60.37% |
Profit margin | 0% |
Book value | $3.57 |
Market capitalisation | $69.1 million |
TTM: trailing 12 months
Atreca share dividends
We're not expecting Atreca to pay a dividend over the next 12 months.
Have Atreca's shares ever split?
Atreca's shares were split on a 1:6 basis on 6 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atreca shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Atreca shares which in turn could have impacted Atreca's share price.
Atreca share price volatility
Over the last 12 months, Atreca's shares have ranged in value from as little as $1.51 up to $9.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atreca's is 0.7785. This would suggest that Atreca's shares are less volatile than average (for this exchange).
Atreca overview
Atreca, Inc. , a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.
Atreca in the news
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
Frequently asked questions
What percentage of Atreca is owned by insiders or institutions?Currently 3.219% of Atreca shares are held by insiders and 61.479% by institutions. How many people work for Atreca?
Latest data suggests 134 work at Atreca. When does the fiscal year end for Atreca?
Atreca's fiscal year ends in December. Where is Atreca based?
Atreca's address is: 835 Industrial Road, South San Francisco, CA, United States, 94070 What is Atreca's ISIN number?
Atreca's international securities identification number is: US04965G1094 What is Atreca's CUSIP number?
Atreca's Committee on Uniform Securities Identification Procedures number is: 04965G109
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert